For its fourth fiscal quarter (ending December 31), BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has reported a -58% decline in E.P.S. from $-0.31 a year ago to $-0.13 in the current quarter. For the latest four quarters through December 31, E.P.S. were $-0.43 compared to $-1.18 a year ago — a decline of -64%.
Recent Price Action
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) stock closed at $8.29 on 2/24/25 after a large decline of -10.0%. Moreover, this decline was accompanied by exceptionally high trading volume at 222% of normal. The stock has declined -6.0% during the last week but has been strong relative to the market over the last nine months.
Current PriceTarget Research Rating
BioCryst Pharmaceuticals is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment